tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Blackham A and Griffiths RJ The effect of FK506 and cyclosporin A on antigen-induced arthritis. 1991 Clin. Exp. Immunol. pmid:1718639
Carobbi A et al. Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. 1991 Transplant. Proc. pmid:1703704
Jain AB et al. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. 1991 Transplant. Proc. pmid:1721274
McMichael J et al. Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 1991 Transplant. Proc. pmid:1721275
Rosborough SL et al. Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. 1991 Transplant. Proc. pmid:1721306
Zeevi A et al. In vitro assessment of FK 506 immunosuppressive activity in transplant patients. 1991 Transplant. Proc. pmid:1721307
Shaw BW et al. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. 1991 Transplant. Proc. pmid:1721338
McDiarmid SV et al. FK 506 rescue therapy in liver transplantation: outcome and complications. 1991 Transplant. Proc. pmid:1721339
Todo S et al. Clinical small bowel or small bowel plus liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721369
Fries D et al. Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. 1991 Transplant. Proc. pmid:1721370
Jain AB et al. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1703354
Wijnen RM et al. Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. 1991 Transplant. Proc. pmid:1721371
Venkataramanan R et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1703355
Viebahn R et al. Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721401
Morrisett JD et al. Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. 1991 Transplant. Proc. pmid:1721402
Brabletz T et al. The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. 1991 Nucleic Acids Res. pmid:1707162
Iwaki Y et al. Replacement of donor lymphoid tissue in small-bowel transplants. 1991 Lancet pmid:1707470
Wu GD et al. FK 506 inhibits the development of transplant arteriosclerosis. 1991 Transplant. Proc. pmid:1721433
Kobayashi N et al. Effect of FK 506 on abdominal organ cluster transplantation in pigs. 1991 Transplant. Proc. pmid:1721434
Markus PM et al. FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. 1991 Surgery pmid:1713358
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Staruch MJ et al. Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. 1991 Int. J. Immunopharmacol. pmid:1721613
Matsuura T et al. [Experimental studies on the mode of action of cyclosporine and FK506 assessed by proliferation response of human cloned T lymphocytes]. 1991 Hinyokika Kiyo pmid:1721767
Romanowski P et al. [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. 1991 Postepy Biochem. pmid:1725924
Altmeyer A et al. Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. 1991 Int. J. Immunopharmacol. pmid:1726093
Gordon RD et al. Liver transplantation at the University of Pittsburgh, 1984 to 1990. 1991 Clin Transpl pmid:1726458
Jiang H et al. Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703702
Jordan ML et al. Initial studies with FK506 in renal transplantation. 1991 Sep-Oct Cleve Clin J Med pmid:1718631
Hanawa H et al. An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats. 1992 Clin. Immunol. Immunopathol. pmid:1371730
Hiraoka Y et al. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis. 1992 J. Pharmacol. Exp. Ther. pmid:1372051
Chen TS et al. Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. 1992 J. Antibiot. pmid:1372307
Morisaki M and Arai T Identity of immunosuppressant FR-900520 with ascomycin. 1992 J. Antibiot. pmid:1372308
Sigal NH and Dumont FJ Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. 1992 Annu. Rev. Immunol. pmid:1375473
Chen TS et al. Microbial transformation of immunosuppressive compounds. II. Specific desmethylation of 13-methoxy group of FK 506 and FR 900520 by an unidentified Actinomycete ATCC 53828 [corrected]. 1992 J. Antibiot. pmid:1375593
Demetris AJ et al. Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. 1992 Lancet pmid:1376851
Ichihashi T et al. Haemolytic uraemic syndrome during FK506 therapy. 1992 Lancet pmid:1376852
O'Keefe SJ et al. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. 1992 Nature pmid:1377361
DiLella AG et al. Chromosomal band assignments of the genes encoding human FKBP12 and FKBP13. 1992 Biochem. Biophys. Res. Commun. pmid:1281998
Sawada M et al. Down regulation of CD4 expression in cultured microglia by immunosuppressants and lipopolysaccharide. 1992 Biochem. Biophys. Res. Commun. pmid:1282000
Minoda M et al. Effects of gamma-interferon and FK506 on resting B cell proliferation of New Zealand black/white F1 mice. 1992 Microbiol. Immunol. pmid:1282197
Yoshimura R et al. A comparative study of cyclosporine vs FK 506: role of kidney microsomal cytochrome P-450. 1992 Transplant. Proc. pmid:1379755
Yamada K et al. FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney--morphologic and biologic analysis. 1992 Transplant. Proc. pmid:1379756
Fukuse T et al. Optimal dose of FK 506 in canine lung allotransplantation. 1992 Transplant. Proc. pmid:1379757
Wada H et al. Combination use of suboptimal doses of FK 506 and cyclosporine in canine lung transplantation. 1992 Transplant. Proc. pmid:1379758
Karpas A et al. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1381509
Yatscoff RW and Shaw LM Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. 1992 Ther Drug Monit pmid:1381530
Arceci RJ et al. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. 1992 Blood pmid:1381629
Pahl A and Keller U FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. 1992 J. Bacteriol. pmid:1381710
Mochizuki M et al. Preclinical and clinical study of FK506 in uveitis. 1992 Curr. Eye Res. pmid:1385045
Chung J et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. 1992 Cell pmid:1377606